Gabelli Funds LLC Acquires 54 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Gabelli Funds LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,859 shares of the biopharmaceutical company’s stock after acquiring an additional 54 shares during the quarter. Gabelli Funds LLC’s holdings in Regeneron Pharmaceuticals were worth $1,789,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Nordea Investment Management AB raised its holdings in Regeneron Pharmaceuticals by 23.2% in the 1st quarter. Nordea Investment Management AB now owns 29,195 shares of the biopharmaceutical company’s stock worth $28,218,000 after acquiring an additional 5,495 shares during the period. Sierra Summit Advisors LLC bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth $1,011,000. Susquehanna Fundamental Investments LLC bought a new position in Regeneron Pharmaceuticals in the 1st quarter worth $1,232,000. Sei Investments Co. raised its holdings in Regeneron Pharmaceuticals by 8.1% in the 1st quarter. Sei Investments Co. now owns 24,407 shares of the biopharmaceutical company’s stock worth $23,487,000 after acquiring an additional 1,839 shares during the period. Finally, Dynamic Technology Lab Private Ltd bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth $749,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN traded up $14.44 on Friday, reaching $1,078.63. The stock had a trading volume of 380,897 shares, compared to its average volume of 386,591. The company has a market capitalization of $118.85 billion, a P/E ratio of 31.87, a price-to-earnings-growth ratio of 2.22 and a beta of 0.13. Regeneron Pharmaceuticals, Inc. has a 1-year low of $723.56 and a 1-year high of $1,106.16. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. The stock has a fifty day moving average price of $1,033.85 and a 200-day moving average price of $977.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The company had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.19 billion. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.36 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on REGN shares. Canaccord Genuity Group restated a “buy” rating and set a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. Morgan Stanley dropped their price objective on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Guggenheim boosted their price objective on shares of Regeneron Pharmaceuticals from $1,040.00 to $1,180.00 and gave the stock a “buy” rating in a report on Thursday, July 18th. TD Cowen boosted their price objective on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Finally, Bank of America boosted their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a report on Friday, April 12th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,074.95.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Michael S. Brown sold 1,172 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the transaction, the director now directly owns 1,382 shares in the company, valued at $1,347,256.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Michael S. Brown sold 1,172 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the completion of the sale, the director now directly owns 1,382 shares of the company’s stock, valued at $1,347,256.52. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Michael S. Brown sold 1,535 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $1,040.00, for a total transaction of $1,596,400.00. Following the sale, the director now directly owns 1,382 shares of the company’s stock, valued at $1,437,280. The disclosure for this sale can be found here. Over the last three months, insiders have sold 65,074 shares of company stock worth $64,546,123. Corporate insiders own 7.48% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.